Hepatitis C Virus (HCV)

The nonstructural (NS) proteins encoding HCV include p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B. The HCV protein NS2 and p7 are essential for viral assembly, while NS3 to NS5B are involved in the membrane-associated RNA replicase complex (RC). NS5A plays a key role in multiple steps of the HCV life cycle by inhibiting Kv2.1 function to prevent intracellular potassium apoptosis and thus blocking hepatocyte cell death. Boceprevir, telaprevir, simeprevir, asunaprevir, grazoprevir and paritaprevir are NS3/4A inhibitors. Ombitasvir, ledipasvir, daclatasvir, elbasvir and velpatasvir are NS5A inhibitors. Sofosbuvir and dasabuvir are NS5B inhibitors. Currently, a combination of two or more direct acting antiviral agents is the cornerstone of treatment for HCV infection.

Chronic hepatitis C virus (HCV) infection is a major cause of chronic liver disease. HCV is a positive-stranded RNA virus grouped in the genus Hepatovirus within the family Flaviviridae. The HCV RNA-dependent RNA polymerase (RdRp) has long been a major target for antiviral development because of its key role in viral replication and the lack of mammalian homologous enzyme. In addition, the combination of luciferone and alpha interferon, the protease inhibitor Telaprevir, the NS5A inhibitor BMS-790052 or the NS5B polymerase inhibitor PSI-7977 synergistically inhibits HCV RNA replication.

CAS No.	Product Name	Inquiry
863884-77-9	Deleobuvir Deleobuvir (BI 207127) is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor.
865466-24-6	Narlaprevir Narlaprevir is a potent, selective, orally bioavailable inhibitor of the hepatitis C virus (HCV) nonstructural protein 3 serine protease that is primarily metabolized by the cytochrome P450-3A4 system.
869901-69-9	MK-2048 MK-2048 is a second generation integrase inhibitor (IC50=2.6 nM). It can inhibits the HIV enzyme integrase 4 times longer than raltegravir.
870142-71-5	ACH-806 ACH-806 is a Hepatitis C virus NS3 protein inhibitor. It can inhibit viral RNA replication in HCV replicon cells and is active in genotype 1 HCV-infected patients in a proof-of-concept clinical trial. But Phase-II for Hepatitis C treatment was discontinued.
876707-99-2	CS-M1995 CS-M1995 is a 4'-Azidocytidine analogue. It can inhibit Hepatitis C virus replication.
876708-01-9	CS-M1996 CS-M1996 is a 4'-Azidocytidine analogue. It can inhibit Hepatitis C virus replication.
876708-03-1	RO-9187 RO-9187 is a potent inhibitor of HCV virus replication in the replicon system. It is excellent substrates for deoxycytidine kinase and were phosphorylated with efficiencies up to 3-fold higher than deoxycytidine. It is a new class of antiviral nucleoside with promising preclinical properties as potential medicines for the treatment of HCV infection.
877130-28-4	(R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp). Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC50s of 59 nM for both isoforms, respectively. Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation.
877225-09-7	HCVP-IN-1 HCVP-IN-1 is an inhibitor of hepatitis C viral polymerase (HCVP).
923590-37-8	Vaniprevir Vaniprevir is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It is a macrocyclic hepatitis C virus NS3/4a protease inhibitor, and is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes. It has good plasma exposure and excellent liver exposure in multiple species.
935735-70-9	ASP5286 ASP5286 is a novel non-immunosuppressive cyclophilin inhibitor for the treatment of HCV.
940908-79-2	R-7128 R-7128 is a selective nucleoside analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, with activity across all HCV genotypes. It is a nucleoside polymerase inhibitor (NPI) and is able to inhibit the RNA synthesis of HCV in vitro.
942123-43-5	Inarigivir soproxil Inarigivir soproxil is an orally active agonist of innate immunity that works via the RIG-I and NOD2 pathways. Inarigivir soproxil exhibits broad-spectrum antiviral activity against resistant HCV variants.
950225-08-8	TTP-8307 TTP-8307, a potent inhibitor of several rhino- and enteroviruses replication, inhibits coxsackievirus B3 (CVB3; EC50 = 1.2 μM) and poliovirus by interfering with the synthesis of viral RNA, and exerts antiviral activity through oxysterol-binding protein (OSBP).
954389-09-4	JTK-853 JTK-853 is a novel, non-nucleoside Hepatitis C Virus (HCV) polymerase inhibitor which shows effective antiviral activity in HCV replicon cells with EC50s of 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively.
958002-33-0	Beclabuvir Beclabuvir is a potent, non-nucleotide inhibitor of HCV NS5B which is currently in Phase III clinical trials for the treatment of chronic HCV infection. Beclabuvir is a thumb site 1-NS5B polymerase ligand. Beclabuvir has been shown to equally inhibit de novo and primer dependent synthesis, 5-75 fold more potently than previously studied compounds, thus resulting the most effective thumb site 1 inhibitor of genotype 1 (GT-1) NS5B polymerase.
133550-34-2	AG 555 AG 555 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (IC50 = 0.7 μM) with 50-fold and >140-fold selectivity over ErbB2 and insulin receptor kinase respectively.
153436-53-4	AG-1478 AG-1478 (NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM; almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.
170449-18-0	AG 1478 hydrochloride The hydrochloride salt form of AG 1478, which has been found to be an epidermal growth factor receptor tyrosine kinase inhibitor.
1228585-88-3	GS 9620 GS 9620 is a potent and oral agonist of TLR7.

※ Please kindly note that our services are for research use only.